Type A and Type B personality theory

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

Retrieved on: 
Monday, August 21, 2023

SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human polyclonal antibodies, without the need for human donors, today reported financial results for the second quarter ended June 30, 2023, and provided a company update.

Key Points: 
  • SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human polyclonal antibodies, without the need for human donors, today reported financial results for the second quarter ended June 30, 2023, and provided a company update.
  • "We are pleased to share the significant progress achieved during the second quarter of 2023.
  • On August 21, 2023, we announced that EisnerAmper LLP was appointed as our independent registered public accounting firm for the fiscal year ending December 31, 2023, effective August 22, 2023.
  • The decrease was primarily due to discretionary cost reduction measures and increased efficiencies as we continue to mature as a publicly traded company.

SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention

Retrieved on: 
Tuesday, May 30, 2023

Dr. Sullivan will present positive clinical data supporting the use of SAB-176 as an effective treatment option for influenza, along with insights into the recent Breakthrough Therapy and Fast Track Designations granted by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • Dr. Sullivan will present positive clinical data supporting the use of SAB-176 as an effective treatment option for influenza, along with insights into the recent Breakthrough Therapy and Fast Track Designations granted by the U.S. Food and Drug Administration (FDA).
  • “We look forward to presenting our platform’s latest advancements and research progress at BIO 2023,” Dr. Sullivan said.
  • “SAB Biotherapeutics is on a transformative journey, leveraging our novel immunotherapy platform to develop innovative therapeutic solutions like SAB-176, which holds tremendous promise in the treatment of influenza.
  • To learn more about partnering opportunities and SAB’s presence at BIO 2023, please contact Sheila Carlson at [email protected] .

SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results

Retrieved on: 
Tuesday, May 16, 2023

SIOUX FALLS, S.D., May 16, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human polyclonal antibodies, without the need for human donors, yesterday reported financial results for the first quarter ended March 31, 2023, and provided a company update.

Key Points: 
  • SIOUX FALLS, S.D., May 16, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human polyclonal antibodies, without the need for human donors, yesterday reported financial results for the first quarter ended March 31, 2023, and provided a company update.
  • "Our first quarter 2023 results demonstrate that we continue to execute on our strategy to develop and deliver powerful immunotherapeutic treatments to patients with significant unmet needs.
  • We remain committed to advancing our programs and delivering much-needed therapies to patients worldwide,” said Eddie J. Sullivan, Ph.D., Co-Founder, President, and Chief Executive Officer of SAB Biotherapeutics.
  • The decrease was primarily due to discretionary cost reduction measures and increased efficiencies as the company continues to mature as a publicly traded company.

SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform

Retrieved on: 
Tuesday, May 9, 2023

SIOUX FALLS, S.D., May 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SAB, Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted fully-human multi-epitope binding immunoglobulin (hIgG) antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today announced the U.S. Food and Drug Administration has approved five of seven sections required for the Company’s pending New Animal Drug Application (NADA) for the company’s antibody-generating platform in Transchromosomic (Tc) bovine.

Key Points: 
  • SAB is in the process of completing the remaining two sections of the NADA.
  • “The FDA has an established regulatory pathway to review our cutting-edge science, and we are pleased to be making significant progress.
  • This process is a one-time approval that will be applicable for all subsequent investigational products produced from the DiversitAb™ platform using our transchromosomic bovine.
  • Recent Breakthrough Therapy and Fast Track designations for one of our leading compounds further support our regulatory path that is well-established and de-risked.

SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference

Retrieved on: 
Thursday, May 4, 2023

SIOUX FALLS, S.D., May 04, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG,) antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today announced the presentation of positive safety and efficacy data from Phase 1 and 2a clinical trials of its influenza immunotherapy, SAB-176 at the AVG conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Seattle, Wash.

Key Points: 
  • Taking place from May 3-5, 2023, the ISIRV-AVG conference is a premier international forum for influenza research, attracting leading experts in the field from around the world.
  • SAB will conduct an oral presentation, titled “Safety and efficacy results from Phase 1 and 2a trials using an anti-Type A and B influenza immunotherapeutic,” on Thursday, May 4, at 11:20 AM PT.
  • "We are excited to present the latest positive findings on SAB-176 at the highly regarded ISIRV-AVG conference," said Eddie Sullivan, co-founder, President and Chief Executive Officer of SAB Biotherapeutics.
  • More information on SAB-176’s influenza therapeutic candidate can be found on the pipeline page of SAB’s website: sab.bio/sab-176 .

SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy

Retrieved on: 
Tuesday, April 18, 2023

SIOUX FALLS, S.D., April 18, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human, multi-epitope binding immunoglobulin (hIgG, or fully human polyclonal) antibodies, without the need for human donors, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to SAB-176, an investigational therapeutic, for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains. On April 13, SAB announced that the FDA had granted Fast Track designation to SAB-176, and that the company had also received FDA guidance and regulatory alignment on advancing SAB-176 into the next phase of development through initiation of a Phase 2b dose-range finding efficacy and safety trial in patient populations at high-risk for developing severe disease.

Key Points: 
  • Products that qualify for Breakthrough Therapy designation receive more benefits than Fast Track products.
  • This Breakthrough Therapy designation signifies an important step forward in our fight against this disease," said Eddie Sullivan, PhD, co-founder, President & CEO of SAB Biotherapeutics.
  • "Even though both designations can be requested early in development, the requirements for Breakthrough Therapy designation are higher than those for the Fast Track program.
  • Preclinical evidence of in vivo efficacy of SAB-176 in the treatment-resistant strains further supports the scientific foundation for this Breakthrough designation.

SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza

Retrieved on: 
Thursday, April 13, 2023

SIOUX FALLS, S.D., April 13, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human, multi-epitope binding immunoglobulin (hIgG) antibodies, without the need for human donors, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains. The Fast Track designation is designed to facilitate accelerated development and expedited review of medicines that treat critical illnesses and address an unmet medical need, with the goal of having promising treatments reaching approval and patients as quickly as possible.

Key Points: 
  • SAB-176 is also being studied in emerging and mutating pandemic strains by targeting multiple epitopes of the virus rather than a single epitope.
  • "We are pleased to receive the FDA Fast Track designation for SAB-176.
  • In addition to the Fast Track designation, SAB Biotherapeutics has also received FDA guidance and regulatory alignment on advancing SAB-176 into the next phase of development, including a Phase 2b trial study design.
  • "SAB-176 has the potential to be a game-changer in the fight against influenza," said Alexandra Kropotova, MD, Chief Medical Officer of SAB Biotherapeutics.

SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference

Retrieved on: 
Thursday, November 3, 2022

SABs Chief Operating Officer Christoph Bausch, Ph.D., led two presentations at the conference on Tuesday, Nov. 1.

Key Points: 
  • SABs Chief Operating Officer Christoph Bausch, Ph.D., led two presentations at the conference on Tuesday, Nov. 1.
  • Tc Bovine, SABs genetically engineered cows, mount the same immune response as humans, only with a much higher concentration of targeted neutralizing antibodies.
  • Data from the in vitro neutralizing capacity of SAB-185 was tested against 10 variant SARS-CoV-2 strains, including several Omicron variants.
  • Our versatile DiversitAb platform is applicable to a wide range of serious unmet needs in human diseases.

Botulinum Toxin Global Market Report 2022: Increased Demand for Non-Surgical Cosmetic Procedures Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, October 14, 2022

The "Botulinum Toxin Market Analysis, By Product, By Applications, By End User, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Botulinum Toxin Market Analysis, By Product, By Applications, By End User, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The increased demand for non-surgical cosmetic procedures and the growing preference for botulinum toxin in the face injectable procedure are factors contributing to the market growth.
  • However, risks related to the use of botulinum toxin in cosmetic treatments and strict government regulations is expected to hinder the growth.
  • Segmentation: Botulinum Toxin Market Report 2021-2029Product (Revenue, USD Million)

SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron

Retrieved on: 
Wednesday, September 28, 2022

Participants received 25 mg/kg of SAB-176 diluted in normal saline or an equivalent volume of normal saline (placebo) in a single IV infusion.

Key Points: 
  • Participants received 25 mg/kg of SAB-176 diluted in normal saline or an equivalent volume of normal saline (placebo) in a single IV infusion.
  • SABs challenge trial for SAB-176 established proof of concept for this important clinical program, said Alexandra Kropotova, M.D., Chief Medical Officer at SAB.
  • The in vitro neutralizing capacity of SAB-185 was tested against 10 variant SARS-CoV-2 strains, including several Omicron variants.
  • This data suggests that SAB-185 may be an effective immunotherapy even in the presence of ongoing viral mutation, Dr. Kropotova said.